Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Randomized Single Ascending Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin Formulations on Postprandial Glucose and Insulin Levels

Next Previous
Trial Profile

Phase 2 Randomized Single Ascending Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin Formulations on Postprandial Glucose and Insulin Levels

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mizagliflozin (Primary)
  • Indications Hypoglycaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vogenx

Most Recent Events

  • 18 Jun 2023 Primary endpoint has been met, (Glucose nadir after mizagliflozin dosing), as per Results presented at the 105th Annual Meeting of the Endocrine Society
  • 18 Jun 2023 Results presented at the 105th Annual Meeting of the Endocrine Society
  • 10 May 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top